Abstract Title: BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7/8) agonist, in combination with pembrolizumab in advanced solid tumors: Phase 1 safety and efficacy results.  Abstract Authors: Manish R. Patel, Anthony W. Tolcher, Drew W. Rasco, Melissa Lynne Johnson, Angela Tatiana Alistar, Lixin Li, Alexander H. Chung, Robert H.I. Andtbacka  Session Title: Poster Discussion […]

Robert Andtbacka, M.D., C.M., Chief Medical Officer, will give a presentation “BDB001, an Intravenously Delivered TLR7/8 Dual Agonist in Advanced Solid Tumors” during The 2nd STING- & TLR-Targeting Therapies Summit, on May 26, 2021. This presentation will highlight the TLR7/8 dual agonist program at Seven and Eight Biopharma and the recent clinical advances. The conference […]

Seven and Eight Biopharma Presents Promising Interim Phase 1 Results for BDB001 at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting SITC 2020 Poster Nov 09, 2020 at 08:00 AM EST EDISON, N.J., Nov. 09, 2020 – Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel […]